论文部分内容阅读
目的探讨调强放射治疗同步多西他赛化疗治疗老年局部晚期非小细胞肺癌的疗效、不良反应及耐受性。方法 35例65岁以上的老年非小细胞肺癌患者(NSCLC)采用调强放射治疗(IMRT),95%计划靶体积(PTV)60Gy,每次2Gy分30次,放射治疗同时每周给予多西他赛35mg/m2,共4～6周。结果总有效率为80.0%(28/35),1年生存率为65.7%,中位生存时间为15.2个月,不良反应较轻,所有患者均能耐受治疗。结论调强放射治疗同步多西他赛化疗是老年局部晚期非小细胞肺癌患者的一种安全有效的治疗手段,能显著改善患者的生存质量,提高生存率,不良反应较轻。
Objective To investigate the efficacy, adverse reactions and tolerability of intensity modulated radiation therapy in combination with docetaxel chemotherapy in elderly patients with locally advanced non-small cell lung cancer. Methods Twenty-five elderly patients with NSCLC aged 65 years and older underwent IMRT with 95% planned target volume (PTV) of 60 Gy, each with 30 Gy of 2Gy. Radiotherapy was given weekly to doxycycline His game 35mg / m2, a total of 4 to 6 weeks. Results The total effective rate was 80.0% (28/35). The 1-year survival rate was 65.7%. The median survival time was 15.2 months. The adverse reactions were mild. All patients were able to tolerate the treatment. Conclusion IMRT chemotherapy combined with docetaxel is a safe and effective treatment for elderly patients with locally advanced non-small cell lung cancer, which can significantly improve the quality of life of patients and improve the survival rate with less adverse reactions.